#USA #Fremont #Alamar Biosciences #NULISAqpcr #pTau217

Alamar Biosciences Introduces NULISAqpcr™ BD-pTau217

In an exciting development within the biomedical field, Alamar Biosciences, a leader in precision proteomics, has recently launched a groundbreaking assay known as NULISAqpcr™ BD-pTau217. This innovative tool represents a major step forward in the non-invasive detection of crucial brain biomarkers associated with Alzheimer's disease and tauopathies.

The Launch of NULISAqpcr™ BD-pTau217

Announced on October 10, 2025, in Fremont, California, the NULISAqpcr™ BD-pTau217 assay is tailored for the quantitative measurement of phosphorylated tau protein 217 (pTau217), a significant biomarker in Alzheimer's research. This unique assay stands out as the only available brain-specific component test, establishing new benchmarks in precision and specificity for central nervous system (CNS) studies related to neurodegeneration.

Developed using Alamar’s patented NULISA™ technology, this assay offers unparalleled sensitivity and specificity for non-invasive sample types, including plasma, serum, and dried blood spots. Importantly, the test measures pTau217 from the CNS directly, eliminating the need for invasive procedures such as lumbar puncture for cerebrospinal fluid (CSF) collection or PET imaging. This advancement effectively lowers the barriers for incorporating this assay into population studies and longitudinal clinical trials aimed at tackling Alzheimer's disease.

Powerful Impact on Alzheimer's Research

Dr. Yuling Luo, the founder and CEO of Alamar Biosciences, expressed enthusiasm regarding the potential of the NULISAqpcr™ BD-pTau217 assay. He stated, "This assay redefines the capabilities of quantitative CNS biomarker detection. By filtering out noise from peripheral tau protein sources, researchers can now detect significant changes in the brain earlier and with greater precision than ever before."

In support of its efficacy, Dr. Jonathan Schott, a neurology professor at University College London, noted the superiority of Alamar’s assays. He remarked, "Our early results suggest that the single-component assay format delivers outcomes at least comparable to traditional plasma pTau217 tests while exhibiting greater multiplexing capability and reducing the number of samples classified as indeterminate. In research settings, brain pTaus measured through multiplex assays show tremendous promise for identifying individuals with high Alzheimer’s pathology who do not yet display symptoms, marking them as candidates for clinical trials of disease-modifying therapies."

The NULISAqpcr™ BD-pTau217 assay will be available in a single-component format or as part of the multiplex NULISAseq™ CNS Disease Panel 120, supporting both discovery and translational research initiatives. The automated workflow of the assay enables processing over 220 samples per day using the ARGO™ HT system, making it ideal for high-throughput analysis in disease cohorts or population studies.

Alamar Biosciences remains committed to collaborating with the neurobiological community to refine biomarker insights that can accelerate progress in treating Alzheimer’s disease and beyond. More information about the NULISAqpcr™ BD-pTau217 assay can be found on the company's website at alamarbio.com.

This assay is intended for research use only and is not for diagnostic applications.

About Alamar Biosciences

Alamar Biosciences, Inc. is a private medical biotechnology firm on a mission to leverage precision proteomics for early disease detection. With its patented NULISA™ platform and the ARGO™ HT system, Alamar seamlessly integrates cutting-edge genomic advancements to achieve unprecedented protein detection sensitivity even at exceptionally low concentrations, significantly surpassing existing market detection technologies.

For further details, please visit alamarbio.com.